Pallidonigroluysian atrophy: Clinicopathological and immunohistochemical studies

Masaru Shimoda, Yoshito Hosoda, Shinsuke Kato, Daizo Kaneto, Kazuro Takahashi, Shu Hui Yen, Eisaku Ohania

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Three autopsied cases of pallidonigroluysian atrophy (PNLA) were studied clinicopathologically and 11 previously reported cases were reviewed for the purpose of clarifying the clinicopathological characteristics of the disease. The main clinical symptoms are parkinsonism, predominantly akinesia or pure akinesia with or without effective levodopa therapy. Major lesions approximately were confined to the globus pallidus, subthalamic nucleus and substantia nigra. Gallyas-Braak method and immunohistochemistry with a monoclonal antibody (mAb) to tau-2 protein (tau-2) revealed a small number of neurofibrillary tangles (NFT) and argyrophilic and tau-2 positive structures within the cytoplasms of the glial cells in the major lesions. Immunohistochemistry with a mAb to Alzheimer NFT (Ab39) demonstrated only a few classical tangles in the globus pallidus in one case. These findings suggest that PNLA can be pathologically differentiated from progressive supranuclear palsy.

Original languageEnglish (US)
Pages (from-to)21-28
Number of pages8
JournalNeuropathology
Volume16
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Neurofibrillary Tangles
Globus Pallidus
Atrophy
Immunohistochemistry
Monoclonal Antibodies
Progressive Supranuclear Palsy
tau Proteins
Subthalamic Nucleus
Parkinsonian Disorders
Levodopa
Substantia Nigra
Neuroglia
Cytoplasm
Therapeutics

Keywords

  • Immunohistochemistry
  • Neurofibrillary tangle
  • Pallidonigroluysian atrophy
  • Progressive supranuclear palsy
  • Pure akinesia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Shimoda, M., Hosoda, Y., Kato, S., Kaneto, D., Takahashi, K., Yen, S. H., & Ohania, E. (1996). Pallidonigroluysian atrophy: Clinicopathological and immunohistochemical studies. Neuropathology, 16(1), 21-28.

Pallidonigroluysian atrophy : Clinicopathological and immunohistochemical studies. / Shimoda, Masaru; Hosoda, Yoshito; Kato, Shinsuke; Kaneto, Daizo; Takahashi, Kazuro; Yen, Shu Hui; Ohania, Eisaku.

In: Neuropathology, Vol. 16, No. 1, 1996, p. 21-28.

Research output: Contribution to journalArticle

Shimoda, M, Hosoda, Y, Kato, S, Kaneto, D, Takahashi, K, Yen, SH & Ohania, E 1996, 'Pallidonigroluysian atrophy: Clinicopathological and immunohistochemical studies', Neuropathology, vol. 16, no. 1, pp. 21-28.
Shimoda M, Hosoda Y, Kato S, Kaneto D, Takahashi K, Yen SH et al. Pallidonigroluysian atrophy: Clinicopathological and immunohistochemical studies. Neuropathology. 1996;16(1):21-28.
Shimoda, Masaru ; Hosoda, Yoshito ; Kato, Shinsuke ; Kaneto, Daizo ; Takahashi, Kazuro ; Yen, Shu Hui ; Ohania, Eisaku. / Pallidonigroluysian atrophy : Clinicopathological and immunohistochemical studies. In: Neuropathology. 1996 ; Vol. 16, No. 1. pp. 21-28.
@article{8913a0599faa4b73b53df62e60d1ff09,
title = "Pallidonigroluysian atrophy: Clinicopathological and immunohistochemical studies",
abstract = "Three autopsied cases of pallidonigroluysian atrophy (PNLA) were studied clinicopathologically and 11 previously reported cases were reviewed for the purpose of clarifying the clinicopathological characteristics of the disease. The main clinical symptoms are parkinsonism, predominantly akinesia or pure akinesia with or without effective levodopa therapy. Major lesions approximately were confined to the globus pallidus, subthalamic nucleus and substantia nigra. Gallyas-Braak method and immunohistochemistry with a monoclonal antibody (mAb) to tau-2 protein (tau-2) revealed a small number of neurofibrillary tangles (NFT) and argyrophilic and tau-2 positive structures within the cytoplasms of the glial cells in the major lesions. Immunohistochemistry with a mAb to Alzheimer NFT (Ab39) demonstrated only a few classical tangles in the globus pallidus in one case. These findings suggest that PNLA can be pathologically differentiated from progressive supranuclear palsy.",
keywords = "Immunohistochemistry, Neurofibrillary tangle, Pallidonigroluysian atrophy, Progressive supranuclear palsy, Pure akinesia",
author = "Masaru Shimoda and Yoshito Hosoda and Shinsuke Kato and Daizo Kaneto and Kazuro Takahashi and Yen, {Shu Hui} and Eisaku Ohania",
year = "1996",
language = "English (US)",
volume = "16",
pages = "21--28",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Pallidonigroluysian atrophy

T2 - Clinicopathological and immunohistochemical studies

AU - Shimoda, Masaru

AU - Hosoda, Yoshito

AU - Kato, Shinsuke

AU - Kaneto, Daizo

AU - Takahashi, Kazuro

AU - Yen, Shu Hui

AU - Ohania, Eisaku

PY - 1996

Y1 - 1996

N2 - Three autopsied cases of pallidonigroluysian atrophy (PNLA) were studied clinicopathologically and 11 previously reported cases were reviewed for the purpose of clarifying the clinicopathological characteristics of the disease. The main clinical symptoms are parkinsonism, predominantly akinesia or pure akinesia with or without effective levodopa therapy. Major lesions approximately were confined to the globus pallidus, subthalamic nucleus and substantia nigra. Gallyas-Braak method and immunohistochemistry with a monoclonal antibody (mAb) to tau-2 protein (tau-2) revealed a small number of neurofibrillary tangles (NFT) and argyrophilic and tau-2 positive structures within the cytoplasms of the glial cells in the major lesions. Immunohistochemistry with a mAb to Alzheimer NFT (Ab39) demonstrated only a few classical tangles in the globus pallidus in one case. These findings suggest that PNLA can be pathologically differentiated from progressive supranuclear palsy.

AB - Three autopsied cases of pallidonigroluysian atrophy (PNLA) were studied clinicopathologically and 11 previously reported cases were reviewed for the purpose of clarifying the clinicopathological characteristics of the disease. The main clinical symptoms are parkinsonism, predominantly akinesia or pure akinesia with or without effective levodopa therapy. Major lesions approximately were confined to the globus pallidus, subthalamic nucleus and substantia nigra. Gallyas-Braak method and immunohistochemistry with a monoclonal antibody (mAb) to tau-2 protein (tau-2) revealed a small number of neurofibrillary tangles (NFT) and argyrophilic and tau-2 positive structures within the cytoplasms of the glial cells in the major lesions. Immunohistochemistry with a mAb to Alzheimer NFT (Ab39) demonstrated only a few classical tangles in the globus pallidus in one case. These findings suggest that PNLA can be pathologically differentiated from progressive supranuclear palsy.

KW - Immunohistochemistry

KW - Neurofibrillary tangle

KW - Pallidonigroluysian atrophy

KW - Progressive supranuclear palsy

KW - Pure akinesia

UR - http://www.scopus.com/inward/record.url?scp=0029938284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029938284&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029938284

VL - 16

SP - 21

EP - 28

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 1

ER -